In their final thoughts, Julie Parsons, MD, and John Brandsema, MD, share insights on the evolving and future SMA treatment landscape.
Julie Parsons, MD: We’re thrilled to have 3 disease-modifying therapies, but each agent can be improved on. We can do the 1.0 and 2.0 drug. We still have room for improvement, and we have new drugs being developed that aren’t necessarily SMN-dependent drugs. Maybe we’ll start working on the muscles. Can we increase the force of the muscle and increase strength? Can we do even better for patients? Adult and young adult patients with SMA [spinal muscular atrophy] complain significantly of fatigue as being a problem, and it gets in the way of their life. Is there another agent that we could use to get rid of the fatigue for these patients so that they have the strength and energy to continue to have active, productive lives? It‘s an incredibly exciting time. This is only the beginning. We’ve made amazing changes and have benefited the patients, but there’s still much more to come. We aren’t done.
John Brandsema, MD: Another very important message that we say to any person living with SMA, their caregivers, the payer system, or other colleagues related to this disease is once we know you have SMA, we need you to be established with an SMA-focused care team for your care for life. This is to optimize the standard of care and because these therapies are new. We need to be vigilant to ensure that we’re assessing the short- and long-term aspects of how these therapies impact the disease and their potential complications in a way that gives the best possible outcome for the person living with the disease. This is an important message that needs to be clear in any care plan and any endorsed approach to this disease. We want you to be connected with people who know this disease and know how to best help you.
Transcript edited for clarity.
SMA Treatments Save Lives and Money, but Economic Barriers Hinder Access
July 19th 2024SMA, a rare genetic neurodegenerative disorder affecting approximately 1 in 10,000 newborns, is typically fatal for untreated children by age two. However, the approval of disease-modifying medications have transformed the treatment landscape.
Read More
Risdiplam Five-Year Follow-Up: 91% of SMA Children Alive, Hitting Milestones
July 11th 2024Risdiplam is an oral small molecule treatment that impacts both the central nervous system and peripheral tissues. Patients receive the medicine daily in liquid form either by feeding tube or by mouth. The drug was first approved by the FDA in 2020 for patients as young as two-months old.
Read More
Can Lecanemab Succeed Where Aduhelm Failed?
September 28th 2022The announcement of positive phase 3 results for the investigational Alzheimer’s disease drug comes against a backdrop of Aduhelm flaming out. Both drugs are predicated on the theory that Alzheimer’s is caused by beta-amyloid deposits.
Read More